Panel backs GSK severe asthma drug in adults, not adolescents
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline won the full support of an FDA advisory panel on 11 June for the company's severe asthma drug mepolizumab as an add-on maintenance treatment in patients with eosinophilic inflammation.